• Source: Doravirine

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
Doravirine was approved for medical use in the United States in August 2018.
Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).




References

Kata Kunci Pencarian:

• Doravirine
• Doravirine/lamivudine/tenofovir
• List of antiviral drugs
• Lamivudine
• ATC code J05
• Reverse-transcriptase inhibitor
• Melanoma
• Cabotegravir/rilpivirine
• Dapivirine Ring
• Islatravir